[Proglumetacin: a flexible and broad-spectrum antirheumatic agent].
Fifty-five patients with osteoarthritis, rheumatoid arthritis or spondyloarthritis, joint pain and other rheumatic-inflammatory disorders were treated with proglumetacin, at different doses, during 3-60 days. Assessment of therapeutic efficacy indicated 88.9% of good results. Joint pain progressively decreased during the whole period of observation. Tolerance was considered good or very good in 78% of patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002648:Child; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007210:Indoleacetic Acids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy; D010146:Pain / Q000188:drug therapy; D010489:Periarthritis / Q000188:drug therapy; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013166:Spondylitis / Q000188:drug therapy
D007210:Indoleacetic Acids; C019541:proglumetacin
Proglumetacina: antireumatico flessibile e ad ampio spettro.